141 related articles for article (PubMed ID: 20073992)
1. Association between HLA-B*4001 and lipodystrophy among HIV-infected patients from Thailand who received a stavudine-containing antiretroviral regimen.
Wangsomboonsiri W; Mahasirimongkol S; Chantarangsu S; Kiertiburanakul S; Charoenyingwattana A; Komindr S; Thongnak C; Mushiroda T; Nakamura Y; Chantratita W; Sungkanuparph S
Clin Infect Dis; 2010 Feb; 50(4):597-604. PubMed ID: 20073992
[TBL] [Abstract][Full Text] [Related]
2. HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients.
Chantarangsu S; Mushiroda T; Mahasirimongkol S; Kiertiburanakul S; Sungkanuparph S; Manosuthi W; Tantisiriwat W; Charoenyingwattana A; Sura T; Chantratita W; Nakamura Y
Pharmacogenet Genomics; 2009 Feb; 19(2):139-46. PubMed ID: 19104471
[TBL] [Abstract][Full Text] [Related]
3. Effects of discontinuing stavudine or protease inhibitor therapy on human immunodeficiency virus-related fat redistribution evaluated by dual-energy x-ray absorptiometry.
Tavassoli N; Bagheri H; Sommet A; Delpierre C; Marion-Latard F; Massip P; Aquilina C; Bonnet E; Obadia M; Labau E; Montastruc JL; Bernard J
Pharmacotherapy; 2006 Feb; 26(2):154-61. PubMed ID: 16466321
[TBL] [Abstract][Full Text] [Related]
4. High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda.
van Griensven J; De Naeyer L; Mushi T; Ubarijoro S; Gashumba D; Gazille C; Zachariah R
Trans R Soc Trop Med Hyg; 2007 Aug; 101(8):793-8. PubMed ID: 17467756
[TBL] [Abstract][Full Text] [Related]
5. Lipodystrophy and dyslipidemia in human immunodeficiency virus-infected Thai patients receiving antiretroviral therapy.
Chuapai Y; Kiertiburanakul S; Malathum K; Sungkanuparph S
J Med Assoc Thai; 2007 Mar; 90(3):452-8. PubMed ID: 17427520
[TBL] [Abstract][Full Text] [Related]
6. Risk factors in human immunodeficiency virus/acquired immunodeficiency syndrome patients undergoing antiretroviral therapy in the state of Pernambuco, Brazil: a case-control study.
Gelenske T; e Farias FA; de Alencar Ximenes RA; de Melo HR; de Albuquerque Mde F; de Carvalho EH; de Medeiros Barros Z; Diniz GT; Filho Dde B
Metab Syndr Relat Disord; 2010 Jun; 8(3):271-7. PubMed ID: 20158442
[TBL] [Abstract][Full Text] [Related]
7. Relationship between HIV/Highly active antiretroviral therapy (HAART)-associated lipodystrophy syndrome and stavudine-triphosphate intracellular levels in patients with stavudine-based antiretroviral regimens.
Domingo P; Cabeza MC; Pruvost A; Salazar J; Gutierrez Mdel M; Mateo MG; Domingo JC; Fernandez I; Villarroya F; Muñoz J; Vidal F; Baiget M
Clin Infect Dis; 2010 Apr; 50(7):1033-40. PubMed ID: 20192724
[TBL] [Abstract][Full Text] [Related]
8. Fat mass ratio: an objective tool to define lipodystrophy in hiv-infected patients under antiretroviral therapy.
Freitas P; Santos AC; Carvalho D; Pereira J; Marques R; Martinez E; Sarmento A; Medina JL
J Clin Densitom; 2010; 13(2):197-203. PubMed ID: 20347364
[TBL] [Abstract][Full Text] [Related]
9. Cervical lipomatosis in HIV-infected patients: a case-control study.
Palacios R; Galindo MJ; Arranz JA; Lozano F; Estrada V; Rivero A; Morales D; Asensi V; del Arco A; Muñoz A; Santos J
HIV Med; 2007 Jan; 8(1):17-21. PubMed ID: 17305927
[TBL] [Abstract][Full Text] [Related]
10. Age and height predict neuropathy risk in patients with HIV prescribed stavudine.
Cherry CL; Affandi JS; Imran D; Yunihastuti E; Smyth K; Vanar S; Kamarulzaman A; Price P
Neurology; 2009 Jul; 73(4):315-20. PubMed ID: 19636052
[TBL] [Abstract][Full Text] [Related]
11. The efficacy and adverse effects of GPO-VIR (stavudine+lamivudine+nevirapine) in treatment-naïve adult HIV patients.
Tin EE; Bowonwatanuwong C; Desakorn V; Wilairatana P; Krudsood S; Pitisuttithum P
Southeast Asian J Trop Med Public Health; 2005 Mar; 36(2):362-9. PubMed ID: 15916042
[TBL] [Abstract][Full Text] [Related]
12. Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis b or c virus co-infection.
Kovari H; Ledergerber B; Battegay M; Rauch A; Hirschel B; Foguena AK; Vernazza P; Bernasconi E; Mueller NJ; Weber R
Clin Infect Dis; 2010 Feb; 50(4):502-11. PubMed ID: 20085465
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia.
Samaras K; Wand H; Law M; Emery S; Cooper D; Carr A
Diabetes Care; 2007 Jan; 30(1):113-9. PubMed ID: 17192343
[TBL] [Abstract][Full Text] [Related]
14. The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients.
Milinkovic A; Martinez E; López S; de Lazzari E; Miró O; Vidal S; Blanco JL; Garrabou G; Laguno M; Arnaiz JA; Leon A; Larrousse M; Lonca M; Mallolas J; Gatell JM
Antivir Ther; 2007; 12(3):407-15. PubMed ID: 17591031
[TBL] [Abstract][Full Text] [Related]
15. Mitochondrial DNA assessment in adipocytes and peripheral blood mononuclear cells of HIV-infected patients with lipodystrophy according to a validated case definition.
Casula M; van der Valk M; Wit FW; Nievaard MA; Reiss P
HIV Med; 2007 Jan; 8(1):32-7. PubMed ID: 17305930
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) in Thai HIV-infected patients.
Kiertiburanakul S; Khongnorasat S; Rattanasiri S; Sungkanuparph S
J Med Assoc Thai; 2007 Feb; 90(2):237-43. PubMed ID: 17375626
[TBL] [Abstract][Full Text] [Related]
17. Influence of antiretroviral therapy on oxidative stress and cardiovascular risk: a prospective cross-sectional study in HIV-infected patients.
Masiá M; Padilla S; Bernal E; Almenar MV; Molina J; Hernández I; Graells ML; Gutiérrez F
Clin Ther; 2007 Jul; 29(7):1448-55. PubMed ID: 17825696
[TBL] [Abstract][Full Text] [Related]
18. Tumour necrosis factor alpha in fat redistribution syndromes associated with combination antiretroviral therapy in HIV-1-infected patients: potential role in subcutaneous adipocyte apoptosis.
Domingo P; Vidal F; Domingo JC; Veloso S; Sambeat MA; Torres F; Sirvent JJ; Vendrell J; Matias-Guiu X; Richart C;
Eur J Clin Invest; 2005 Dec; 35(12):771-80. PubMed ID: 16313254
[TBL] [Abstract][Full Text] [Related]
19. Correlates of risk of adipose tissue alterations and their modifications over time in HIV-1-infected women treated with antiretroviral therapy.
Galli M; Ridolfo AL; Adorni F; Cappelletti A; Morelli P; Massetto B; Piazza M; Gianelli E; Vaccarezza M; Gervasoni C; Moroni M
Antivir Ther; 2003 Aug; 8(4):347-54. PubMed ID: 14518704
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine.
Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Saekang N; Pairoj W; Chantratita W
J Clin Virol; 2008 Apr; 41(4):310-3. PubMed ID: 18316243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
